Speaker Hastert adds health policy advisor
Executive Summary
House Energy & Commerce Committee Chief Health Counsel Chuck Clapton joins the office of Speaker Dennis Hastert (R-Ill.) as policy adviser for healthcare and social security issues. Clapton was with the E&C Committee when Billy Tauzin, now CEO of PhRMA, served as chairman. Clapton has supported FDA, even when the agency faced strong criticism from others for its handling of drug safety. Following the COX-2 inhibitor fallout on Capitol Hill, Clapton stated that FDA was doing a "very good job" and that there was no need for "sweeping or comprehensive reforms" (1"The Pink Sheet" April 11, 2005, p. 15)...
You may also be interested in...
Senate HELP committee adds staffer
Sen. Mike Enzi, R-Wyo., ranking member of the Senate Health, Education, Labor and Pensions Committee, announces Chuck Clapton has joined the committee's minority staff as health policy director. His previous experience includes extensive work in the drug reimbursement area. Clapton most recently served as chief health counsel for Republican staff of the House Ways and Means Committee after working as a health care policy advisor for former Speaker Dennis Hastert, R-Ill. (1"The Pink Sheet," April 3, 2006, In Brief). He also served as health counsel to then House Energy & Commerce Committee Chair Billy Tauzin, R-La., during the drafting of the Medicare Modernization Act
Bextra On Capitol Hill: FDA’s “Turning Point” Or Another Sign Of Failure?
FDA's request for Pfizer to withdraw the COX-2 inhibitor Bextra could signal a new era of strong decision making at FDA, Senate Finance Committee Chairman Charles Grassley (R-Iowa) declared
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.